If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Water packs === Water packs are flat and leak-proof plastic containers used in the interiors of cold boxes and vaccine carriers. These containers are set to the appropriate temperature depending on the type of vaccine being transported. The temperature could range from -10° to +24 °C and does not last that long before coming back to the same temperature as the surroundings.
(1.2) Keey et al. (2000) use a different definition of the fibre saturation point (equilibrium moisture content of wood in an environment of 99% relative humidity). Many properties of wood show considerable change as the wood is dried below the fibre saturation point, including:
l-DOPA, also known as l-3,4-dihydroxyphenylalanine and used medically as levodopa, is made and used as part of the normal biology of some plants and animals, including humans. Humans, as well as a portion of the other animals that utilize l-DOPA, make it via biosynthesis from the amino acid l-tyrosine. l-DOPA is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), which are collectively known as catecholamines. Furthermore, l-DOPA itself mediates neurotrophic factor release by the brain and central nervous system. In some plant families (of the order Caryophyllales), l-DOPA is the central precursor of a biosynthetic pathway that produces a class of pigments called betalains. l-DOPA can be manufactured and in its pure form is sold as a drug with the INNTooltip International Nonproprietary Name levodopa. As a drug, it is used in the treatment of Parkinson's disease and dopamine-responsive dystonia, as well as restless leg syndrome. l-DOPA has a counterpart with opposite chirality, d-DOPA. As is true for many molecules, the human body produces only one of these isomers (the l-DOPA form). The enantiomeric purity of l-DOPA may be analyzed by determination of the optical rotation or by chiral thin-layer chromatography.
BBC article on Salisbury's School of Embalming Infection risks and embalming by KS Creely. Institute of Occupational Medicine Research Report TM/04/01 Archived at Ghostarchive and the Wayback Machine: TED (14 October 2011), Jae Rhim Lee: My mushroom burial suit, retrieved 1 February 2017
==== Enzyme-linked immunosorbent assay ==== The enzyme-linked immunosorbent assay (ELISA) technique used for the analysis of YTXs is a recently developed method by Briggs et al. This competitive, indirect immunoassay uses polyclonal antibodies against YTX to determine its concentration in the sample. The assay is commercially available, and is a rapid technique for the analysis of YTXs in shellfish, algal cells, and culture samples. ELISA has several advantages: it is very sensitive, has a limit of quantification of 75 μg/kg, is relatively cheap, and is easy to carry out. The major disadvantage to this method is it cannot differentiate between the different YTX analogues and takes a long time to generate results.
Sources: en.wikipedia.org
=== Pathomechanisms === A great understanding of how MYBPC3 mutations lead to the development of inherited cardiomyopathy came from the analyses of human myocardial samples, gene transfer in different cell lines, naturally occurring or transgenic animal models and more recently disease modeling using induced pluripotent stem cells (iPSC)-derived cardiac myocytes. Although access to human myocardial samples is difficult, at least some studies provided evidence that truncated cMyBP-Cs, resulting from truncating MYBPC3 mutations are not detectable in human patient samples by Western-immunoblot analysis. This was supported in heterozygous Mybpc3-targeted knock-in mice, carrying the human c.772G>A transition (i.e. founder mutation in Tuscany These data suggest haploinsufficiency as the main disease mechanism for heterozygous truncating mutations. A body of evidence exists that the mechanisms regulating the expression of mutant allele involve the nonsense-mediated mRNA decay, the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway after gene transfer of mutant MYBPC3 in cardiac myocytes or in mice in vivo. In contrast to truncating mutations, missense mutations lead, in most of the cases (although difficult to specifically detect), to stable mutant cMyBP-Cs that are, at least in part, incorporated into the sarcomere and could act as poison polypeptides on the structure and/or function of the sarcomere.
=== Former === Jeff Jones – lead vocals, bass (1968) John Rutsey – drums, percussion, backing vocals (1968–1974; died 2008), lyrics (1968–1973) Joe Perna – bass, lead and backing vocals (1969) Lindy Young – keyboards, backing and lead vocals, guitars, percussion, harmonica (1969) Bob Vopni – guitars, backing vocals (1969) Mitch Bossi – guitars, backing vocals (1971–1972) Neil Peart – drums, percussion, lyrics (1974–2015; died 2020)
The 327th was soon transferred to help form the 101st Airborne Division and was replaced by the 504th Parachute Infantry Regiment, leaving the division with two regiments of glider infantry and one of parachute infantry. In February 1943 the division received another change when the 326th was transferred to the 13th Airborne Division, being replaced by the 505th Parachute Infantry Regiment, under James M. Gavin, then a colonel, who was later to command the division.
Both photos became symbolic of the suffering of victims of the Bhopal disaster, and Bartholomew went on to win the 1985 World Press Photo of the Year. Within a few days, trees in the vicinity became barren, and bloated animal carcasses had to be disposed of. 170,000 people were treated at hospitals and temporary dispensaries, and 2,000 buffalo, goats, and other animals were collected and buried. Supplies, including food, became scarce owing to suppliers' safety fears. Fishing was prohibited, causing further supply shortages. Lacking any safe alternative, on 16 December, tanks 611 and 619 were emptied of the remaining MIC by reactivating the plant and continuing the manufacture of pesticide. Despite safety precautions such as having water-carrying helicopters continually overflying the plant, this led to a second mass evacuation from Bhopal. The Government of India passed the "Bhopal Gas Leak Disaster Act" that gave the government rights to represent all victims, whether or not in India. Complaints of lack of information or misinformation were widespread. An Indian government spokesman said, "Carbide is more interested in getting information from us than in helping our relief work". Formal statements were issued that air, water, vegetation, and foodstuffs were safe, but people were warned not to consume fish. The number of children exposed to the gases was at least 200,000. Within weeks, the State Government established a number of hospitals, clinics, and mobile units in the gas-affected area to treat the victims. S. Ravi Rajan (Prof. Environmental Studies, U.C.
5-Hydroxytryptophan (5-HTP) can also be administered through a transdermal patch, which was launched in the United Kingdom in early 2014. Rivastigmine, an Alzheimer's treatment medication, was released in patch form in 2007 under the brand name Exelon. In December 2019, Robert S. Langer and his team developed and patented a technique whereby transdermal patches could be used to label people with invisible ink in order to store medical information subcutaneously. This was presented as a boon to "developing nations" where lack of infrastructure means an absence of medical records. The technology uses a "quantum dot dye that is delivered along with a vaccine". Caffeine patches, designed to deliver caffeine to the body through the skin.
Sources: en.wikipedia.org
=== Miniature time of flight === Some researchers are successful in designing a series of miniature TOF mass analyzers. Cotter at Johns Hopkins University used a pulsed extraction in linear time of flight mass analyzer and the ions are accelerated to with higher energy of 12 keV to enable detection of high-mass. The group achieved resolutions of 1/1200 and 1/600 at m/z 4500 and 12000 respectively. This mini analyzer can measure 66k Da proteins, mixtures of oligonucleotides, and biological spores. Verbeck at University of North Texas, created a mini-TOF based on reflectron TOF with a microelectromechanical system technology. To overcome the low resolution of short flight tube, the effective ion travelling path length is extended by moving ions back and forth in periods of time. The system used a 5-cm endcap reflectron TOF with higher-order kinetic energy focusing to analyze the ions with m/z exceeding 60,000. Ecelberger, a senior professional staff scientist in the Sensor Science Group of the Research and Technology Development Center at APL also developed a suitcase TOF incorporated with matrix-assisted laser desorption/ionization MALDI. The suitcase TOF was tested by scientists from U.S. Army Soldier and Biological Chemical Command. The samples are biological toxins and chemical agents with the mass range from a few hundred daltons to over 60 kDa. The Suitcase TOF was referenced with a commercial TOFMS for the same experiments. Both instruments can detect all but a few compounds with very encouraging results.
variation in the contents prior to packaging variation in the packaging components variation in the product and packaging processes variation in storage, distribution, cold chain, etc. variation in the quantity of contents
== Beginning of the war == On September 1, 1939, Hitler's Germany began its invasion of Poland, marking the beginning of World War II. On September 4, President Lázaro Cárdenas, faithful to Mexico's pacifist policy, declared neutrality in the European conflict, which was seen as a new kind of war. However, neutrality did not prevent the government from condemning aggression against the sovereignty of democratic nations. Mexico recognized the Polish government-in-exile, and in December 1939, it criticized the Soviet invasion of Finland. In 1940 and 1941, Mexico condemned the German invasions of Norway, the Netherlands, Belgium, Greece and Yugoslavia. Before the German aggression against Holland and Belgium, Cárdenas declared on May 13, 1940 that:
== External links == Lipoprotein(a) at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08519 (Apolipoprotein(a)) at the PDBe-KB.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.